25 / 31
SPIRITT
: Randomized P-II trial of FOLFIRI panitumumab or
bev after first-line FOLFOX/bev in
wt KRAS
mCRC
Hecht JR et al. Clin Colorectal Cancer 2015
DFS
Panitumumab: 7.7m
Bevacizumab: 9.2m
HR 1.01 95%CI 0.68-1.50; p 0.97
OS
Panitumumab: 18 meses
Bevacizumab: 21.4 meses
HR 1.06 (95% CI, 0.75-1.49; 0.75)